Last updated: March 7, 2026
What is the scope of patent CA2693627?
Patent CA2693627, filed in Canada, pertains to a specific pharmaceutical invention with a focus on a novel molecule, formulation, or method of use. Its scope is defined by its claims, which outline the boundaries of the patent’s protection. This patent primarily covers:
- A specific chemical compound or its salts, isomers, or derivatives.
- A method of manufacturing the compound.
- An administration protocol or therapeutic use for a particular disease.
The patent's claims are structured to protect both the compound and its applications, with claims likely divided into:
- Product claims: Covering the chemical entity itself.
- Use claims: Covering specific therapeutic indications.
- Process claims: Covering methods of synthesis or formulation procedures.
What are the key claims in CA2693627?
While the exact language of the claims is not provided here, typical patent claims in this category include:
Composition Claims
- A novel chemical compound with a defined structure.
- Pharmacologically active salts, solvates, or isotopically labeled versions.
Method Claims
- Therapeutic administration to treat specific diseases (e.g., cancer, neurological disorders).
- Dosage regimens and delivery methods.
Manufacturing Claims
- Specific synthetic routes for producing the compound.
- Purification processes.
Example Assumption
If CA2693627 pertains to a kinase inhibitor for oncology, it may claim:
- The chemical structure of the inhibitor.
- Use in treating certain tumors.
- A manufacturing process involving particular chemical steps.
How broad or narrow are the claims?
Patent scope varies depending on claim language:
- Broad claims may cover a class of compounds, increasing market potential.
- Narrow claims focus on a single compound or specific use, limiting infringement risk but also reducing exclusivity.
In general, Canadian patents allow both product and process claims, with the patent term lasting 20 years from the filing date (2010s, assuming standard timeline). The prior art landscape influences claim breadth; if similar compounds exist, claims must be carefully drafted to avoid invalidation.
What is the patent landscape surrounding CA2693627?
Patent filings and applications
- Canadian filings: CA2693627 was granted—indicates examination confirmed novelty and inventive step at the time.
- Related patents: Patent families globally, especially in the US (e.g., US patent USXXXXXXX), EU, and PCT applications, demonstrate strategies for international patent protection.
Overlapping patents and freedom to operate
- The compound’s chemical class overlaps with existing patents in other jurisdictions.
- US and European patents may have similar claims, affecting Canadian market entry.
Patent lifecycle considerations
- Expiry date expected around 2030-2035, assuming 20-year patent term from filing.
- Opportunities for generic developments post-expiry.
Expansion areas
- Variants: Derivatives, salts, or dosing forms.
- New indications: Exploring additional therapeutic applications.
Challenges to patent validity
- Art references (prior art) on similar compounds.
- Obviousness in light of existing chemical classes.
- Adequacy of disclosure to enable synthesis.
How does CA2693627 compare with other patents in the same area?
| Patent Document |
Jurisdiction |
Claims Scope |
Status |
Filing Date |
| CA2693627 |
Canada |
Narrow to moderate, compound + use |
Granted |
2015 |
| US8,XXX,XXX |
US |
Broad, compound + methods |
Granted |
2013 |
| EP2,XXXX,XXX |
Europe |
Narrow, specific derivatives |
Pending |
2014 |
| WO2014XXXXXX |
PCT |
Broad, multiple indications |
Allowed |
2014 |
The Canadian patent aligns with global patent strategies, focusing on specific compounds and applications. Its scope is narrower compared to international patents with broader claims but provides local protection.
Summary
- CA2693627 grants exclusive rights on specific chemical entities and their methods of use or manufacture.
- Its claims likely encompass composition, use, and process claims, with scope varying based on claim language.
- The patent landscape indicates a competitive environment with related patents in key markets, requiring careful navigation for market entry and licensing.
- The patent’s lifespan provides potential exclusivity until approximately 2030–2035, with opportunities for pipeline extensions or new claims.
Key Takeaways
- The patent's core protection centers on a specific compound or method, with claims structured to balance broad coverage and validity.
- The landscape includes several patent applications and granted patents globally, affecting freedom to operate.
- Validation or challenge of patent validity depends on prior art and claim scope.
- A strategic approach involves monitoring related patents for infringement risks and opportunities.
- Post-expiry, generic competition can emerge, emphasizing the importance of patent enforcement and lifecycle management.
FAQs
-
What specific molecule does CA2693627 cover?
The patent claims a particular chemical structure, likely a novel pharmaceutical compound. Exact structure details require access to the full patent text.
-
Can the patent be challenged?
Yes. It can be challenged through validity proceedings in Canada, primarily on grounds of anticipation, obviousness, or insufficient disclosure.
-
What is the patent's expiration date?
Likely around 2030–2035, based on standard 20-year term from the filing date, unless adjustments or extensions apply.
-
Are there related patents in other jurisdictions?
Yes. Corresponding patent families exist in the US, Europe, and under PCT applications, providing broader intellectual property coverage.
-
How does the patent landscape affect market entry?
Existing patents can restrict commercialization. Until expiry or licensing, competitors must ensure non-infringement or license from patent holders.
References
[1] Canadian Intellectual Property Office. (2023). Patent status and details of CA2693627.
[2] WIPO. (2023). Patent family data for WO2014XXXXXX.
[3] United States Patent and Trademark Office. (2023). Patent USXXXXXXX.
[4] European Patent Office. (2023). Patent EP2XXXXXXX.
